Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Downgrades Arrowhead Research (ARWR) to Hold
-
Ocular Therapeutix (OCUL) Enters $40M Controlled Equity Offering Sales Agreement
-
NewLink Genetics (NLNK) Enters $40M Stock Controlled Equity Offering Sales Agreement
-
Nabriva Announces Terms of Rights Offering
-
Avino Announces Closing of Bought Deal Offering
-
Harte Gold Announces $25 Million Financing
-
Harte Gold Announces $25 Million Financing
-
After-Hours Stock Movers 11/23: (CTRP) (IIIN) Higher; (AIRG) (CRBP) Lower (more...)
-
Corbus Pharma (CRBP) Lower after Entering Agreement with Cantor on $35M Common Stock Offering
-
U.S. shares end at record highs for second day, oil steadies
-
Unusual 11 Mid-Day Movers 11/22: (SKLN) (CDNA) (BURL) Higher; (AMDA) (CHNR) (ASM) Lower
-
Avino Silver & Gold Mines (ASM) Enters $10M Bought-Deal Common Stock Offering
-
Avino Announces Bought Deal Offering of US$10 Million
-
Anthony LeCour Joins Dresner Partners as Managing Director
-
Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
-
Lupus Research Alliance Pounds America's Pavements, Raising $3 Million to Cure Lupus
-
Glaukos (GKOS) PT Bumped to $45 at Cantor Fitzgerald
-
Synthetic Biologics (SYN) Prices 25M Shares at $1.00/Share
-
Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
-
Synthetic Biologics (SYN) Commences Offering of Common Stock and Warrants
-
Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
-
Cantor Fitzgerald Upgrades Healthcare Realty Trust (HR) to Buy
-
Cantor Fitzgerald Reiterates Bullish View on Corbus Pharmaceuticals (CRBP) on Resunab Success
-
Glaukos (GKOS) PT Raised to $45 at Cantor Fitzgerald
-
Form 4 BGC Partners, Inc. For: Nov 07 Filed by: CANTOR FITZGERALD, L. P.
-
Orchid Island Capital Announces November 2016 Monthly Dividend and October 31, 2016 RMBS Portfolio Characteristics
-
Aurinia Establishes At-The-Market Facility
-
Construction, pharma, gold miners seen as Europe's top Trump trades
-
Titan Pharmaceuticals Reports Third Quarter 2016 Financial Results
-
Cantor Fitzgerald Downgrades DepoMed Inc (DEPO) to Hold
-
Rambler Metals and Mining: Notice of AGM
-
Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights
-
InVivo Therapeutics Reports 2016 Third Quarter Financial Results and Business Update
-
Cantor Fitzgerald Starts AngioDynamics (ANGO) at Buy
-
Cantor Fitzgerald Adds Three Senior Fixed Income Salespeople
-
Cantor Fitzgerald Reiterates Sell on bluebird bio (BLUE) Following ASH Abstracts
-
Notable Analyst Rating Changes 11/2: (SQ) (NUE) (SU) Upgraded; (ILMN) (H) (BKD) Downgraded
-
Alignvest Acquisition Corporation and Trilogy International Partners LLC Announce Proposed Business Combination
-
Cantor Fitzgerald Starts Bellicum Pharmaceuticals (BLCM) at Buy
-
Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock
-
Signal Genetics (SGNL) to Merge with Miragen Therapeutics
-
Orchid Island Capital Announces Third Quarter 2016 Results
-
Theravance Biopharma (TBPH) Prices 3.85M Shares, $200M Conv. Notes Offerings
-
Cantor Fitzgerald Starts Cidara Therapeutics (CDTX) at Buy
-
Theravance Biopharma Announces Pricing of Public Offerings of 3,850,000 Ordinary Shares and $200 Million of 3.25% Convertible Senior Notes due 2023
-
Abeona Therapeutics (ABEO) Prices 6M Shares at $7/Share
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
-
Dynavax Secures Committed Financing From Deerfield for $100 Million of Senior Secured Notes
-
Theravance Biopharma (TBPH) Announces $100M Shares, $150M Conv. Stock Offerings
-
Theravance Biopharma Announces Proposed Public Offerings of $100 Million of Ordinary Shares and $150 Million of Convertible Senior Notes

